| Top Adding |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Real Estate > Buying > Phoenix, Scottsdale And Surrounding Areas - First Quarter Market Recap 2007 |
|
Top Adding - Phoenix, Scottsdale And Surrounding Areas - First Quarter Market Recap 2007
Nearly 60,000 homes in Phoenix, Scottsdale and surrounding areas! That’s right, that’s the number of listings ( According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product single family homes only) Arizonan's are dealing with in the first quarter of this year. It’s an incredible number but NOT compa ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ed to previous years. 64,553 listings in 2006, and 70,000 listings in 2005 were listed, sold, or in the process of a contract du lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ing the first quarter of the year. So you can say that the market is off to a “slower start” this year. However, there’s good ne here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe s to come…Over the last three years, the number of current listings in the Phoenix area has remained steady, staying right aroun d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro 42,000. This year, out of the 60,000 homes, only 18% have sold with an average price of $367,500 and with another 10% currently ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc pending with a contract on them. Comparing those numbers to the two previous years, the market this year is UP by 3.2% easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi Late February & March helped bring up those numbers. It looks like it could continue to stay strong through the late s nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically mmer. Hopefully, interest rates will continue to remain low. Let’s talk about sales price for a minute. In 2005, the average sal and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ s price (in the first quarter) was $285,459. So, in the last two years Maricopa County's average sales price increased b ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi 29%! Now, that’s the “hit” this market is facing. Have wages increased by that amount in the last two years? Across th ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a e nation, an average percentage of increase in value per year is approx. 3-4%. Arizonan's are truly fortunate to live in one of dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod he most desirable & fastest growing areas in the country. With our annual average percent of increase in value being 8-12%, what cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin are we complaining about? The positive message being conveyed is that of the 11,000 homes that have sold this year in the Phoen tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen x area, the sellers got over 96% of their asking price. These sellers were realistic t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel n pricing their properties. They still had to wait an average of 120 days, but their patience paid off. (Last year it took only ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust 60 days) With so much on the market for a buyer to choose from, why buy the house that is overpriced? Broken down into price ran y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products es that make sense, the homes priced from $100,000 to $300,000 made up 60% of the sales in the first quarter of this year. The p . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ice range from $300,000 to $600,000 accounted for another 30%. Consistently within all price ranges, the sales price was 95-96% elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip f the listed price. It’s a Great Buyer’s market AND a Great Seller’s market! It’s a Great Life! tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Analysis Of The Success And Failure Of Doing Business In China How to Make Money Through Your Ecommerce Website
|